Related Experiment Videos
Current strategies for controlling postprandial hyperglycaemia
1Department of Internal Medicine, Annweiler Hospital, Annweiler, Germany.
Insights
Glycosylated haemoglobin (HbA1c) may not fully capture postprandial glucose spikes in diabetes. Rapid-acting insulin analogues offer improved postprandial glucose control and treatment flexibility for type 2 diabetes management.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Glycosylated haemoglobin (HbA1c) is a standard measure for blood glucose control in diabetes mellitus.
- HbA1c may not accurately reflect short-term postprandial glucose excursions, which can impact diabetic complications.
- Postprandial hyperglycemia is increasingly linked to cardiovascular events in type 2 diabetes.
Purpose of the Study:
- To evaluate the efficacy of rapid-acting insulin analogues in managing postprandial hyperglycemia in type 2 diabetes.
- To compare the effects of rapid-acting insulin analogues with regular human insulin on glucose control.
- To highlight the clinical advantages of using rapid-acting insulin analogues as a first-line therapy.
Main Methods:
- Review of clinical studies and epidemiological data on glucose control in type 2 diabetes.
- Analysis of the pharmacokinetic and pharmacodynamic profiles of rapid-acting insulin analogues versus human insulin.
- Assessment of clinical practice benefits, including treatment flexibility and hypoglycemia risk.
Main Results:
- Rapid-acting insulin analogues demonstrate superior postprandial glucose reduction compared to regular human insulin.
- These analogues offer faster absorption, higher insulin peaks, and enhanced suppression of hepatic glucose release.
- Clinical use shows advantages such as treatment flexibility, no weight gain, stable doses, and fewer hypoglycemic episodes.
Conclusions:
- Rapid-acting insulin analogues are effective in managing postprandial glucose excursions in type 2 diabetes.
- Early adoption of rapid-acting insulin analogues in multiple daily injection regimens is recommended.
- These analogues represent a valuable therapeutic option for improving glycemic control and potentially reducing long-term complications.
Abstract:
In patients with diabetes mellitus glycosylated haemoglobin (HbA1c), which reflects mean glycaemic values in the previous 3 months, is typically used as a clinical measure of blood glucose control. However, it does not always correlate satisfactorily with postprandial blood glucose excursions, which may occur only for a few hours and be insufficient to alter HbA1c formation. Thus, postprandial glucose peaks may have a significant impact on diabetic complications but not be monitored sufficiently from HbA1c measurements. Epidemiological studies have shown stronger correlations for incidence of cardiovascular events with postprandial glucose levels than with preprandial levels. Results from the UKPDS suggest that HbA1c had to be reduced below 7 per cent to ameliorate macrovascular outcomes. In patients with type 2 diabetes there is a loss of the first phase insulin response so a logical treatment strategy is to use a rapid-acting insulin analogue. Rapid-acting insulin analogues have a greater effect on postprandial glucose levels than regular human insulin. This is due to the faster absorption and higher insulin peak in blood, but also due to the increased ability of rapid-acting analogues to suppress hepatic glucose release. In clinical practice, preprandial injection of rapid-acting insulin reveals significant advantages including treatment flexibility, lack of weight gain, stable insulin doses and reduction of hypoglycaemic episodes. These effects are more pronounced if this type of therapy is used early in the course of the disease. Thus rapid-acting insulin analogues are being increasingly used as first-line therapy with multiple daily injection in patients with type 2 diabetes.